Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGATO: lomustine with or without reirradiation for first progression of glioblastoma
2023-505267-36-00Phase 3Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of lomustine in glioblastoma (GBM) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Planned start Mar 2024; status: authorised.
02
Drugs
lomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-505267-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505267-36-00.